GlaxoSmithKline Pharmaceuticals Limited(IN:GLAXO)
₹2,669.55+14.25 (+0.54%)
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited financials statements
₹2,669.55
At close:+14.25 (+0.54%)
Want to see IN:GLAXO full AI Analyst Report?
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) Financial Statements
7 Followers
GlaxoSmithKline Pharmaceuticals Limited Financial Overview
GlaxoSmithKline Pharmaceuticals Limited's market cap is currently ₹452.24B. The company's EPS TTM is ₹67.68; its P/E ratio is 39.38; and it has a dividend yield of 2.13%. GlaxoSmithKline Pharmaceuticals Limited has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | ₹ 38.22B | ₹ 37.26B | ₹ 34.42B | ₹ 32.26B | ₹ 32.64B |
| Gross Profit | ₹ 16.65B | ₹ 22.53B | ₹ 20.22B | ₹ 18.68B | ₹ 18.14B |
| Operating Income | ₹ 12.60B | ₹ 11.14B | ₹ 8.38B | ₹ 7.48B | ₹ 6.99B |
| EBITDA | ₹ 14.75B | ₹ 13.28B | ₹ 8.88B | ₹ 9.04B | ₹ 8.49B |
| Net Income | ₹ 10.36B | ₹ 9.28B | ₹ 5.90B | ₹ 6.11B | ₹ 16.95B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | ₹ 27.56B | ₹ 24.98B | ₹ 18.57B | ₹ 16.54B | ₹ 29.03B |
| Total Assets | ₹ 43.24B | ₹ 41.08B | ₹ 35.57B | ₹ 33.27B | ₹ 46.33B |
| Total Debt | ₹ 332.70M | ₹ 99.50M | ₹ 186.65M | ₹ 155.40M | ₹ 200.76M |
| Net Debt | ₹ -10.69B | ₹ -13.94B | ₹ -455.06M | ₹ -194.00M | ₹ -2.66B |
| Total Liabilities | ₹ 20.56B | ₹ 21.57B | ₹ 17.79B | ₹ 15.85B | ₹ 19.70B |
| Stockholders' Equity | ₹ 22.67B | ₹ 19.51B | ₹ 17.78B | ₹ 17.41B | ₹ 26.63B |
| Cash Flow | |||||
| Free Cash Flow | ₹ 9.67B | ₹ 12.67B | ₹ 5.51B | ₹ 4.40B | ₹ 7.76B |
| Operating Cash Flow | ₹ 10.22B | ₹ 12.90B | ₹ 5.82B | ₹ 4.84B | ₹ 8.11B |
| Investing Cash Flow | ₹ 2.78B | ₹ -458.10M | ₹ 87.12M | ₹ 8.08B | ₹ -4.06B |
| Financing Cash Flow | ₹ -7.37B | ₹ -7.69B | ₹ -5.61B | ₹ -15.43B | ₹ -5.24B |
Currency in INR

